AzTrials
AzTrials

Organ TransplantationNCT06652919

Survey on the Evaluation of Medication Information Leaflets for Organ Transplant Patients

An observational study of Organ Transplantation, run by Universität Münster at 1 site in Germany.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The aim of this study is to collect feedback from organ transplant patients or their caregivers/relatives on the medication information leaflets we've developed, using a questionnaire, and to adjust the content to better meet the specific needs of this unique patient group. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Organ Transplantation
How many people
30 participants
Where
1 siteGermany
Study dates
6 Nov 2024to Mar 2025
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients who have undergone solid organ transplantation (kidney, liver, heart, lung) or their caregivers/family members

Who may be able to join

  • Patients who have undergone solid organ transplantation (kidney, liver, heart, lung)
  • Caregivers or family members of organ transplant patients
  • German-speaking individuals
  • adult

Who cannot join

  • Individuals who are not able to provide consent
  • Non-German-speaking individuals
  • under 18 years old
  • Patients who have undergone organ transplantation and are no longer taking immunosuppressants

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Germany1 site, 1 recruiting
  • Institute of Pharmaceutical and Medicinal Chemistry, Clinical Pharmacy, University of Münster

    Münster, North Rhine-Westphalia, 48149

    Georg Hempel, Prof. Dr., +49 251 83-33334, georg.hempel@uni-muenster.de

    Li-Yun Chen

    Recruiting

Other trials in Germany

About this study

Official title: Development and Validation of Materials for the Pharmaceutical Care of Organ Transplant Recipients in Community Pharmacy: Survey on the Evaluation of Medication Information Leaflets for Organ Transplant Patients

The aim of this study is to collect feedback from organ transplant patients or their caregivers/relatives on the medication information leaflets we've developed, using a questionnaire, and to adjust the content to better meet the specific needs of this unique patient group.

Read the detailed description

Introduction:

Organ transplantation is a life-saving procedure, but it also marks the beginning of a lifelong journey for patients. In 2023 alone, over 3,600 organ transplants were performed in Germany, with kidney, liver, heart, and lung transplants being the most common. Following a transplant, patients must take a combination of immunosuppressive medications to prevent their body from rejecting the new organ. These drugs, while essential, come with significant risks. Many of which have a very narrow therapeutic range and a high risk of drug interactions. Additionally, these medications have unique side effects that can affect mortality and health-related quality of life (HRQOL). As a result, organ transplant patients require constant medical monitoring and comprehensive education about their medications to ensure long-term graft survival and a better quality of life.

Community pharmacies in Germany have recognized the need to support these patients. Since 2022, community pharmacies have been offering pharmaceutical care services specifically tailored to organ transplant recipients, focusing on safe medication use and personalized counseling, including brown-bag reviews. This service is covered by health insurance and aims to reduce administration errors, improve therapy adherence, and enhance overall patient safety. However, despite nearly 4,000 new organ transplants each year, only a small fraction of these patients-less than 3%-benefit from these services annually. The reality is that public pharmacies rarely interact with transplant patients, as they make up a small group. Furthermore, there is currently a lack of adequate materials to support the provision of this service for transplant patients.

This research project addresses this gap by developing and validating specific materials that will help pharmacies deliver high-quality pharmaceutical care to organ transplant recipients. A key element of this project is the medication information leaflets designed by the investigators, which aim to enhance patients' understanding of their immunosuppressive therapy, reduce medication use errors, and ultimately improve medication safety.

The aim of this study is to collect feedback from organ transplant patients or their caregivers/relatives on these medication leaflets, using a questionnaire instrument called "Adapted Consumer Information Rating Form (CIRF)", developed by Krass et al. The results will help the investigators evaluate the quality of the medication information leaflets in terms of their content and design. This will also assist the investigators in adjusting the content to better meet the specific needs of this unique patient group in the future.

Study design:

This pilot study is designed as a descriptive survey. It involves a one-time survey, either online or in paper form, that collects data on participants' evaluations and opinions regarding the medication information sheets. The instrument that is used, the original Adapted CIRF, was initially translated by the investigators through a peer review process, including cultural adaptation from English to German. After two rounds of peer review, the final version was produced. Permission for the use and translation of the original Adapted CIRF was obtained from Krass et al. Additionally, demographic data will be collected in the study. This study was approved by the Ethics Committee: Ethik-Kommission der Ärztekammer Westfalen-Lippe und der Westfälischen Wilhelms-Universität Münster.

The recruitment of the participants will be conducted through cooperating pharmacies and patient self-help groups, and participation in the questionnaire is voluntary. Data protection measures will be taken into account to ensure the confidentiality and security of participants' information.

Procedure for participation in the study:

  1. The study begins as soon as the participants have agreed to the consent form.
  2. The study consists of two parts. In Part 1, participants are asked to select a medication information sheet and thoroughly read it.
  3. In Part 2, participants will ask to complete the questionnaire.
  4. After completing the questionnaire, the participation is considered finished. The process will take approximately 10 to 20 minutes.
Keywords
Organ transplantation, Consumer Information Rating Form, Pharmaceutical Care, Community Pharmacy, Patient Information Leaflets

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Consumer Information Rating Form (CIRF): Mean "comprehensibility" score, mean "future use" score, mean "utility" score and mean "design quality" score.

    In this research, the measurement instrument called the Consumer Information Rating Form (CIRF) is used, though the content has been slightly adapted to fit our study. It was developed as a direct method for quantifying consumers' perceptions of written patient information, including their views on its comprehensibility, utility, and overall design quality.

    In the questionnaire, four perspectives will be evaluated using Likert scales, including "comprehensibility" (5 items, with a total score range from 5 to 25), "future use" (3 items, with a total score range from 3 to 15), "utility" (5 topics with two perspectives: the amount of information provided and its usefulness, with a total score range from 3 to 20.), and "design quality" (6 items, with a total score range from 6 to 30). Higher scores indicate better quality of the patient information leaflet.

    Measured: 3 months

  2. Participants' characteristics

    Gender, age group, highest level of education, current employment status, if participant has worked in the healthcare system, Which patient information leaflet did the participant evaluate? What type of organ transplant has the participant or the person they look after received? (Kidney, liver, heart, or lung transplant), How long has it been since the transplant?

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Oct 2024
  2. Study start6 Nov 2024 (estimated)
  3. Primary completionJan 2025 (estimated)
  4. Study completionMar 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06652919
Sponsor's protocol ID
Clinical Pharmacy Uni MS_2024
Status last verified
Nov 2024
First submitted
16 Oct 2024
Last updated
8 Nov 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Organ Transplantation, run by Universität Münster at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 8 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Li-Yun Chen (+49 (0) 251 83-32173, liyun.chen@uni-muenster.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Consumer Information Rating Form (CIRF): Mean "comprehensibility" score, mean "future use" score, mean "utility" score and mean "design quality" score. (time frame: 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Nov 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in